Calamos Advisors LLC Takes $1.21 Million Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Calamos Advisors LLC bought a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 19,479 shares of the company’s stock, valued at approximately $1,205,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in AMPH. Court Place Advisors LLC acquired a new stake in Amphastar Pharmaceuticals in the fourth quarter valued at approximately $340,000. Guidance Capital Inc. grew its position in Amphastar Pharmaceuticals by 4.5% in the 4th quarter. Guidance Capital Inc. now owns 7,476 shares of the company’s stock valued at $466,000 after purchasing an additional 324 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Amphastar Pharmaceuticals by 14.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,792 shares of the company’s stock valued at $667,000 after purchasing an additional 1,356 shares in the last quarter. Lam Group Inc. raised its holdings in Amphastar Pharmaceuticals by 2.2% during the fourth quarter. Lam Group Inc. now owns 130,800 shares of the company’s stock worth $8,090,000 after buying an additional 2,800 shares during the last quarter. Finally, Louisiana State Employees Retirement System acquired a new position in shares of Amphastar Pharmaceuticals during the fourth quarter valued at about $1,157,000. 65.09% of the stock is owned by institutional investors.

Analysts Set New Price Targets

AMPH has been the topic of a number of analyst reports. StockNews.com lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. JPMorgan Chase & Co. started coverage on Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They issued an “overweight” rating and a $60.00 price objective for the company. Finally, Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, April 10th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $66.00.

Amphastar Pharmaceuticals Stock Up 3.5 %

Amphastar Pharmaceuticals stock opened at $40.01 on Monday. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $35.62 and a fifty-two week high of $67.66. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.70 and a current ratio of 2.17. The firm’s 50-day simple moving average is $45.96 and its 200 day simple moving average is $51.14. The stock has a market cap of $1.96 billion, a PE ratio of 15.51, a price-to-earnings-growth ratio of 0.95 and a beta of 0.84.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.03). The business had revenue of $178.11 million during the quarter, compared to analysts’ expectations of $174.90 million. Amphastar Pharmaceuticals had a return on equity of 26.95% and a net margin of 21.34%. Research analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.43 EPS for the current fiscal year.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 500 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $53.10, for a total value of $26,550.00. Following the completion of the transaction, the director now owns 80,333 shares in the company, valued at approximately $4,265,682.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 500 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $53.10, for a total value of $26,550.00. Following the sale, the director now owns 80,333 shares of the company’s stock, valued at $4,265,682.30. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Michael A. Zasloff sold 12,500 shares of the stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total transaction of $589,750.00. Following the transaction, the director now directly owns 21,326 shares of the company’s stock, valued at $1,006,160.68. The disclosure for this sale can be found here. Over the last three months, insiders have sold 14,000 shares of company stock worth $660,860. 28.40% of the stock is owned by company insiders.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.